Currently, two Japanese Encephalitis vaccines are available: JESPECT and IMOJEV.
JESPECT is an inactivated, cell culture-derived vaccine that is given as a 2-dose schedule, 28 days apart. It is currently only for use in those above 18 years of age. The duration of protection for JESPECT is currently unknown and is still being studied.
A booster dose is recommended 12 months after the initial course, in the event of continuing risk to Japanese Encephalitis.
IMOJEV is a live attenuated viral vaccine, that is given as a single dose and can be administered to children as young as 12 months old. It is likely to provide protection for more than 5 years.
Both JESPECT and IMOJEV are considered to have good protective efficacy, however, they are expensive compared to other travel vaccinations. Side effects of may include fever, headache or muscle aches in 10% of recipients.
| Age at Vaccination | Vaccine | Number of doses | Booster |
|---|---|---|---|
| > 2 months to < 18 years | JEspect | 2 doses (28 days apart) |
After 12 months if continuing risk |
| > 9 months to < 18 years | Imojev | 1 dose | 1-2 years after primary dose if ongoing risk of JE |
| 18 years | Imojev | 1 dose | Not required |
| JEspect | 2 doses (28 days apart) |
1-2 years after primary dose if ongoing risk of JE virus exposure |